I am not quite following your line of thinking here. Your link to to the clinicaltrials.gov site and the Phase 3 trials for T2 diabetes, which is the trial that was initiated later and so, we have heard (?), will complete enrollment later.
The pertinent information pasted from the site:
| Estimated Enrollment: |
328 |
| Study Start Date: |
November 2011 |
| Estimated Study Completion Date: |
February 2013 |
| Estimated Primary Completion Date: |
December 2012 (Final data collection date for primary outcome measure)
|
| Responsible Party: |
Mannkind Corporation ( Mannkind Corporation ) |
| ClinicalTrials.gov Identifier: |
NCT01451398 History of Changes
|
| Other Study ID Numbers: |
MKC-TI-175, Affinity2 |
| Study First Received: |
October 7, 2011 |
| Last Updated: |
July 3, 2012 |
| Health Authority: |
United States: Food and Drug Administration
|
Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
|
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
|
ClinicalTrials.gov processed this record on July 08, 2012
If this info in bold has in fact been updated it would mean that the trials are now on schedule to be completed by year end (12 weeks titration and then 12 weeks of Afrezza therapy) and submitted by Feb 2013, which is good news. Yes?
